---
title: "Bristol Myers Squibb SVP, Controller Phil M. Holzer sells 500 shares for $33,750"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297084433.md"
description: "Bristol Myers Squibb SVP and Controller Phil M. Holzer sold 500 common shares on August 25, 2026, at $67.5 per share, totaling $33,750. Following the transaction, Holzer held 16,862 shares. The information was published via EDGAR by Bristol-Myers Squibb Company."
datetime: "2026-08-26T20:21:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297084433.md)
  - [en](https://longbridge.com/en/news/297084433.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297084433.md)
generator: "portal-rs"
---

# Bristol Myers Squibb SVP, Controller Phil M. Holzer sells 500 shares for $33,750

-   Bristol-Myers Squibb SVP and Controller Phil M. Holzer sold 500 common shares on Aug. 25, 2026 at $67.5. \* Holzer held 16,862 shares following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002012588-26-000004), on August 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares](https://longbridge.com/en/news/296941366.md)
- [Archer Investment Corp Takes $1.40 Million Position in Bristol Myers Squibb Company $BMY](https://longbridge.com/en/news/297393102.md)
- [BUZZ-Cytokinetics rises after heart disease drug shows promise in late-stage study](https://longbridge.com/en/news/297310247.md)
- [BREAKINGVIEWS-AstraZeneca's blocked M&A signals tough CEO finale](https://longbridge.com/en/news/296766497.md)
- [Antelope Enterprise announces private placement of unregistered Class A ordinary shares](https://longbridge.com/en/news/297327460.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**